Stock Earnings

Question 1

What are Crinetics Pharmaceuticals Inc's key financial statements?

Accepted Answer

According to the latest financial statement (Form-10K), Crinetics Pharmaceuticals Inc has a total asset of $1,126, Net loss of $-465

Question 2

What are the key financial ratios for CRNX?

Accepted Answer

Crinetics Pharmaceuticals Inc's Current ratio is 8.4, has a Net margin is -6,642.85, sales per share of $0.07.

Question 3

How is Crinetics Pharmaceuticals Inc's revenue broken down by segment or geography?

Accepted Answer

Crinetics Pharmaceuticals Inc largest revenue segment is Novel Therapeutics, at a revenue of 7,696,000 in the most earnings release.For geography, United States is the primary market for Crinetics Pharmaceuticals Inc, at a revenue of 7,696,000.

Question 4

Is Crinetics Pharmaceuticals Inc profitable?

Accepted Answer

no, according to the latest financial statements, Crinetics Pharmaceuticals Inc has a net loss of $-465

Question 5

Does Crinetics Pharmaceuticals Inc have any liabilities?

Accepted Answer

yes, Crinetics Pharmaceuticals Inc has liability of 134

Question 6

How many outstanding shares for Crinetics Pharmaceuticals Inc?

Accepted Answer

Crinetics Pharmaceuticals Inc has a total outstanding shares of 95.57

Breakdown	TTM	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Revenue	18	7	1	4	4	1
Revenue Growth (YoY)	--	600%	-75%	0%	300%	--
Cost of Revenue	1	1	--	--	--	--
Gross Profit	15	6	--	--	--	--
Selling, General & Admin	206	191	99	58	42	24
Research & Development	355	332	240	168	130	84
Operating Expenses	562	523	339	226	172	108
Other Non Operating Income (Expenses)	0	0	0	-23	-27	0
Pretax Income	-496	-465	-297	-209	-162	-107
Income Tax Expense	--	0	0	--	--	--
Net Income	-496	-465	-298	-214	-163	-107
Net Income Growth	51%	56%	39%	31%	52%	47%
Shares Outstanding (Diluted)	104.09	94.05	80.78	58.07	51.98	38.44
Shares Change (YoY)	12%	16%	39%	12%	35%	26%
EPS (Diluted)	-4.76	-4.94	-3.69	-3.69	-3.15	-2.8
EPS Growth	35%	34%	0%	17%	13%	16%
Free Cash Flow	-419	-383	-234	-173	-116	-89
Free Cash Flow Per Share	-4.02	-4.07	-2.89	-2.97	-2.23	-2.31
Gross Margin	83.33%	85.71%	--	--	--	--
Operating Margin	-3,027.77%	-7,371.42%	-33,800%	-5,550%	-4,175%	-10,700%
Profit Margin	-2,755.55%	-6,642.85%	-29,800%	-5,350%	-4,075%	-10,700%
Free Cash Flow Margin	-2,327.77%	-5,471.42%	-23,400%	-4,325%	-2,900%	-8,900%
EBITDA	-541	-513	-336	-221	-167	-107
EBITDA Margin	-3,005.55%	-7,328.57%	-33,600%	-5,525%	-4,175%	-10,700%
D&A For EBITDA	4	3	2	1	0	0
EBIT	-545	-516	-338	-222	-167	-107
EBIT Margin	-3,027.77%	-7,371.42%	-33,800%	-5,550%	-4,175%	-10,700%
Effective Tax Rate	--	0%	0%	--	--	--

Crinetics Pharmaceuticals Inc (CRNX) Price

CRNX Stock Price Chart

CRNX Income

Follow-Up Questions